Valuation: Roche Holding AG

Market Cap 283B 347B 305B 260B 489B 33,419B 496B 3,366B 1,315B 16,430B 1,303B 1,275B 56,807B P/E 2026 *
19.2x
P/E 2027 * 17.6x
Enterprise Value 294B 360B 316B 270B 507B 34,655B 515B 3,490B 1,364B 17,038B 1,351B 1,322B 58,908B EV / Sales 2026 *
4.69x
EV / Sales 2027 * 4.39x
Free-Float
88.78%
Yield 2026 *
2.82%
Yield 2027 * 2.88%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 347B
+0.86%+1.43%+47.17%+161.40% 1,067B
+1.59%+4.09%+56.51%+52.79% 635B
+0.95%+1.91%+36.30%+83.13% 458B
-0.60%+1.52%+36.67%+39.80% 295B
-0.14%+0.60%+17.29%+18.19% 262B
+0.09%-2.82%-29.09%-41.29% 216B
+1.22%+2.66%+22.66%+59.81% 203B
-1.18%-3.70%+11.28%+67.43% 161B
-0.16%-2.04%-1.01%-33.78% 140B
Average +0.13%+0.41%+21.98%+45.28% 381.82B
Weighted average by Cap. +0.46%+1.35%+34.39%+78.45%

Financials

2026 *2027 *
Net sales 62.65B 76.7B 67.36B 57.49B 108B 7,386B 110B 744B 291B 3,631B 288B 282B 12,555B 65.41B 80.08B 70.34B 60.03B 113B 7,712B 115B 777B 303B 3,792B 301B 294B 13,110B
Net income 14.67B 17.96B 15.77B 13.46B 25.29B 1,730B 25.68B 174B 68.06B 850B 67.42B 65.97B 2,940B 16.33B 19.99B 17.56B 14.99B 28.16B 1,925B 28.59B 194B 75.76B 947B 75.06B 73.44B 3,273B
Net Debt 10.48B 12.83B 11.27B 9.62B 18.07B 1,236B 18.35B 124B 48.62B 607B 48.16B 47.12B 2,100B 3.75B 4.59B 4.03B 3.44B 6.46B 442B 6.56B 44.52B 17.39B 217B 17.23B 16.86B 751B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA